PYPD - PolyPid Ltd.
NASDAQ
->
Healthcare
->
Biotechnology
Petah Tikva,
Israel
Type: Equity
PYPD price evolution
PYPD
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3.08 | $3.84 | $5.31 | |
| Short term investments | $6.27 | $10.61 | ||
| Net receivables | $0.1 | |||
| Inventory | ||||
| Total current assets | $10.45 | $9.78 | $15.09 | $6.07 |
| Long term investments | ||||
| Property, plant & equipment | $8.88 | $9.49 | $10.08 | $9.22 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $19.59 | $19.53 | $25.4 | $15.37 |
| Current liabilities | ||||
| Accounts payable | $1.64 | $0.99 | $1.29 | $0.77 |
| Deferred revenue | ||||
| Short long term debt | $6.31 | $5.3 | $4.54 | |
| Total current liabilities | $10.48 | $10.29 | $9.2 | $7.29 |
| Long term debt | $2.53 | $3.13 | $4.29 | $6.38 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $17.44 | $17.93 | $18.25 | $17.47 |
| Shareholders' equity | ||||
| Retained earnings | -$258.81 | -$251.05 | -$244.76 | -$238.31 |
| Other shareholder equity | ||||
| Total shareholder equity | $1.6 | $7.14 | -$2.1 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.31 | $8.55 | $9.82 | $4.32 |
| Short term investments | $4.04 | $22.38 | $40.16 | |
| Net receivables | $0.1 | $0.24 | $0.6 | |
| Inventory | ||||
| Total current assets | $6.07 | $14.19 | $34.81 | $47.2 |
| Long term investments | ||||
| Property, plant & equipment | $9.22 | $11.68 | $8.76 | $5.89 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $28.65 | |||
| Total investments | ||||
| Total assets | $15.37 | $25.97 | $44.23 | $75.85 |
| Current liabilities | ||||
| Accounts payable | $0.77 | $1.14 | $4.14 | $0.97 |
| Deferred revenue | ||||
| Short long term debt | $4.54 | $4.98 | ||
| Total current liabilities | $7.29 | $8.55 | $7.81 | $2.88 |
| Long term debt | $6.38 | $7.57 | ||
| Total noncurrent liabilities | $0.19 | |||
| Total debt | ||||
| Total liabilities | $17.47 | $20.14 | $8.01 | $3.07 |
| Shareholders' equity | ||||
| Retained earnings | -$238.31 | -$214.44 | -$174.62 | -$132.29 |
| Other shareholder equity | ||||
| Total shareholder equity | -$2.1 | $5.83 | $36.23 | $72.78 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $6.12 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0 | |||
| Interest expense | -$0.17 | |||
| Net income | ||||
| Net income | -$6.29 | |||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $22.87 | $26.27 | ||
| Operating income | -$26.27 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.07 | |||
| Interest expense | -$0.93 | |||
| Net income | ||||
| Net income | -$23.86 | -$36.87 | ||
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 29 Oct 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$6.21 | $3.8 | -$7.86 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $12.5 | $9.98 | $10.98 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.2 | -$3.46 | -$5.16 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$39.56 | -$42.6 | -$36.87 | |
| Operating activities | ||||
| Depreciation | $1.72 | $1.12 | $1.01 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$34.32 | -$32.39 | -$21.6 | |
| Investing activities | ||||
| Capital expenditures | -$1.77 | -$2.65 | -$0.78 | |
| Investments | ||||
| Total cash flows from investing | $3.8 | $16.58 | $36.9 | -$40.77 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $4.75 | $1.03 | $62.77 | |
| Net borrowings | $11.31 | |||
| Total cash flows from financing | $9.98 | $16.43 | $1.03 | $62.77 |
| Effect of exchange rate | $0.53 | |||
| Change in cash and equivalents | -$3.46 | -$1.31 | $5.55 | $0.41 |
News
Fundamentals
| Market cap | $16.67M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 6.80M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -8.32 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.00 |
| Quick ratio | N/A |